Allogeneic Hematopoietic Cell Transplantation for Patients with Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN)

Investigators reported on all 17 patients with BPDCN who underwent allogeneic hematopoietic cell transplantation (allo-HCT) at their center between 2000 and 2020, and concluded that allo-HCT provided long-lasting remissions in BPDCN patients, particularly when performed in complete remission.
[Bone Marrow Transplantation]
[zotpress userid=’7992332′ items=’AAAAAAAA’ style=’apa’ cite=’yes’]
Abstract
Bookmark

No account yet? Register

Share

Features of Repertoire Diversity and Gene Expression in Human Cytotoxic T Cells Following Allogeneic Hematopoietic Cell Transplantation

Scientists showed the features of repertoire diversity and the gene expression profile of HLA-A24 cytomegalovirus-specific cytotoxic T cells in actual recipients according to the cytomegalovirus reactivation pattern.
[Communications Biology]
[zotpress userid=’7992332′ items=’AAAAAAAA’ style=’apa’ cite=’yes’]
Full Article
Bookmark

No account yet? Register

Share

CAR T Cells with Dual Targeting of CD19 and CD22 in Pediatric and Young Adult Patients with Relapsed or Refractory B Cell Acute Lymphoblastic Leukemia: A Phase I Trial

Researchers conducted a Phase I trial in pediatric and young adult patients with relapsed or refractory B cell acute lymphoblastic leukemia to test AUTO3, autologous transduced T cells expressing both anti-CD19 and anti-CD22 chimeric antigen receptors (CARs).
[Nature Medicine]
[zotpress userid=’7992332′ items=’BBBBBBBB’ style=’apa’ cite=’yes’]
Full Article
Bookmark

No account yet? Register

Share

Posttransplant Blockade of CXCR4 Improves Leukemia Complete Remission Rates and Donor Stem Cell Engraftment without Aggravating GVHD

The authors found that posttransplant treatment with the CXCR4 antagonist AMD3100 significantly improved the eradication of leukemia cells in the bone marrow in patient-derived xenograft mice grafted with B cell acute lymphoblastic leukemia cells from multiple patients.
[Cellular & Molecular Immunology]
[zotpress userid=’7992332′ items=’BBBBBBBB’ style=’apa’ cite=’yes’]
Abstract
Bookmark

No account yet? Register

Share

Insufficiency of FZR1 Disturbs HSC Quiescence by Inhibiting Ubiquitin-Dependent Degradation of RUNX1 in Aplastic Anemia

Investigators reported that FZR1 was downregulated in severe aplastic anemia HSCs compared with healthy control and was associated with decreased quiescence of HSCs.
[Leukemia]
[zotpress userid=’7992332′ items=’BBBBBBBB’ style=’apa’ cite=’yes’]
Abstract
Bookmark

No account yet? Register

Share

A CIBERSORTx-Based Immune-Cell Scoring System Could Independently Predict Prognosis of Myelodysplastic Syndrome Patients

The authors adopted CIBERSORTx to estimate the relative fractions of 22 subtypes of immune cells in the bone marrow of 316 myelodysplastic syndrome patients and correlated the results with clinical outcomes.
[Blood Advances]
[zotpress userid=’7992332′ items=’BBBBBBBB’ style=’apa’ cite=’yes’]
Abstract
Bookmark

No account yet? Register

Share

Leukemic Progenitor Cells Enable Immunosuppression and Post-Chemotherapy Relapse via IL-36–Inflammatory Monocyte Axis

Researchers showed that abnormal IL-36 production activated by NF-κB was an essential feature of mouse and human leukemic progenitor cells.
[Science Advances]
[zotpress userid=’7992332′ items=’BBBBBBBB’ style=’apa’ cite=’yes’]
Full Article
Bookmark

No account yet? Register

Share

p300 Suppresses the Transition of Myelodysplastic Syndromes to Acute Myeloid Leukemia

Scientists identified a tumor suppressor role of the acetyltransferase p300 in clinically relevant myelodysplastic syndromes models driven by mutations in the epigenetic regulators TET2, ASXL1, and SRSF2.
[JCI Insight]
[zotpress userid=’7992332′ items=’BBBBBBBB’ style=’apa’ cite=’yes’]
Full Article
Bookmark

No account yet? Register

Share

Gates Biomanufacturing Facility Announces Strategic Manufacturing Partnership with Cell Therapy Pioneer, Nkarta

The Gates Biomanufacturing Facility signed a continued strategic agreement with Nkarta to manufacture clinical supply of therapeutic Natural Killer cells. As part of this collaboration, GBF will continue to manufacture NKX101, an immunotherapy currently in a Phase I clinical trial for patients with relapsed/refractory acute myeloid leukemia or higher-risk myelodysplastic syndromes.
[Gates Biomanufacturing Facility]
[zotpress userid=’7992332′ items=’nan’ style=’apa’ cite=’yes’]
Press Release
Bookmark

No account yet? Register

Share

Sutro Biopharma and BioNova Pharmaceuticals Enter into Collaboration for STRO-001 in Greater China

Sutro Biopharma, Inc and BioNova Pharmaceuticals Limited announced an option agreement for BioNova to develop and commercialize STRO-001, a CD74-targeting Antibody-Drug Conjugate, for patients with hematologic cancers, in Greater China, including mainland China, Hong Kong, Macau and Taiwan.
[Sutro Biopharma, Inc.]
[zotpress userid=’7992332′ items=’nan’ style=’apa’ cite=’yes’]
Press Release
Bookmark

No account yet? Register

Share

Emerging Approaches to Improve Allogeneic Hematopoietic Cell Transplantation Outcomes for Non-malignant Diseases

Scientists discuss the current approach to each of these clinical issues and how emerging novel therapeutics hold promise to advance transplant care for patients with non-malignant diseases.
[Blood]
[zotpress userid=” items=’AAAAAAAA’ style=’apa’ cite=’yes’]
Abstract
Bookmark

No account yet? Register

Share
Share